Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer

The clinical application of immune checkpoint inhibitors (ICIs) has led to dramatic changes in the treatment strategy for patients with advanced non-small cell lung cancer (NSCLC). Despite the observation of improved overall survival in NSCLC patients treated with ICIs, their efficacy varies greatly...

Descripción completa

Detalles Bibliográficos
Autores principales: Miura, Yosuke, Sunaga, Noriaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115923/
https://www.ncbi.nlm.nih.gov/pubmed/30060457
http://dx.doi.org/10.3390/cancers10080245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115923/
https://www.ncbi.nlm.nih.gov/pubmed/30060457
http://dx.doi.org/10.3390/cancers10080245

Ejemplares similares